Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE36939 E
Publication typeGrant
Application numberUS 08/652,690
Publication dateOct 31, 2000
Filing dateMay 30, 1996
Priority dateMar 22, 1991
Also published asCA2063529A1, DE69215722D1, DE69215722T2, DE69215722T3, EP0504881A2, EP0504881A3, EP0504881B1, EP0504881B2, EP0732106A2, EP0732106A3, US5315998, US6585678, US20030191446, US20080274097
Publication number08652690, 652690, US RE36939 E, US RE36939E, US-E-RE36939, USRE36939 E, USRE36939E
InventorsKatsuro Tachibana, Shunro Tachibana
Original AssigneeEkos Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
A booster comprising a plenty of microbubbles of a gas and drug in a liquid, diffusion and penetration of the medicament into the body by applying ultrasound; transdermal drug delivery
US RE36939 E
Abstract
A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4107 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.
Images(2)
Previous page
Next page
Claims(18)
What is claim is:
1. A .[.booster.]. .Iadd.composition .Iaddend.for enhancing effects of ultrasound in the therapy of diseases, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. a medicament.Iadd.; .Iaddend.and
.[.b..]. microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..
2. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the microbubbles are formed from air or oxygen gas in the liquid.
3. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the liquid is a 3 to 5% human serum albumin solution.
4. A pharmaceutical liquid composition for the therapy of diseases with application of ultrasound, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd.; .Iaddend.and
.[.b..]. a medicament selected from the group consisting of thrombolytic agents, hormones, antibiotics and antineoplastic agents.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..
5. The composition according to claim 4, wherein the microbubbles are formed from air or oxygen gas in the liquid.
6. The composition according to claim 4, wherein the liquid is a 3 to 5% human serum albumin solution. .[.7. The composition according to claim 4, wherein the medicament is a member selected from thromobolytic agents,
hormones, antibiotics, and antineoplastic agents..].8. The composition according to claim 4, wherein the medicament is selected from the group consisting of urokinase, tissue plasminogen activator, insulin,
theophylline, and lidocaine. 9. A method for enhancing the therapeutic effects of a medicament, comprising:
.[.a. applying ultrasound to a pharmaceutical liquid composition according to claim 4 and
b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition .Iadd.comprising a liquid, a medicament, and microbubbles of a gas having a diameter of 0.1 to 100 μm, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 10. The method according to claim 9, wherein the liquid composition comprises about 4107 cells/ml of microbubbles .[.of a gas having a diameter of 0.1 to 100 μm and a medicament in the liquid.]..
. The method according to claim 10, wherein the liquid is a 3 to 5%
human serum albumin solution. 12. The method according to claim 9, wherein the medicament is selected from the group consisting of urokinase, tissue
plasminogen activator, insulin, theophylline, and lidocaine. 13. A method of dosing subjects with a pharmaceutical preparation by:
.[.a. applying ultrasound to a pharmaceutical liquid composition and.].
.[.b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition comprising .Iadd.a liquid, .Iaddend.microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd., .Iaddend.and a medicament .[.in a liquid in the therapy of diseases.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 14. The method of dosing according to claim 13, wherein the microbubbles
are formed from air or oxygen gas in the liquid. 15. The method of dosing according to claim 13, wherein the liquid is a 3 to 5% human serum albumin
solution. 16. The method of dosing according to claim 13, wherein the medicament is selected from the group consisting of urokinase, tissue
plasminogen activator, insulin, theophylline, and lidocaine. .Iadd.17. A composition for enhancing the effects of ultrasound in the therapy of diseases when said ultrasound is administered in conjunction with a medicament, said composition comprising a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 μm, wherein a majority of the medicament is present outside of the shell and is not incorporated in the shell. .Iaddend..Iadd.18. A composition for enhancing the effects of ultrasound in the therapy of diseases which comprises a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 μm, wherein at least a majority of the medicament is present outside of the shell.
.Iaddend..Iadd.9. A method for enhancing the therapeutic effects of ultrasound comprising:
creating a mixture comprising a liquid, microbubbles of a gas having a diameter of 0.1 to 100 μm, and a medicament, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the mixture. .Iaddend..Iadd.20. The method of claim 19 wherein the mixture is administered in proximity to a diseased part. .Iaddend..Iadd.21. The method of claim 19 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.22. A method for enhancing the therapeutic effect of a medicament administered to a patient comprising:
administering to the patient a liquid composition comprising microbubbles of a gas having a diameter of 0.1 to 100 μm; and
applying ultrasound to the liquid composition and the medicament, wherein a majority of the medicament is present outside of the microbubbles. .Iaddend..Iadd.23. The method of claim 22 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.24. A method of enhancing the therapeutic effects of ultrasound of a medicament comprising:
creating microbubbles of a gas having a diameter of 0.1 to 100 μm in a liquid containing the medicament, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the microbubbles. .Iaddend..Iadd.25. The method of claim 24 wherein the liquid is administered in the proximity of a diseased part. .Iaddend..Iadd.26. The method of claim 24 wherein the liquid is injected in a blood vessel near the diseased part. .Iaddend.
Description

This invention relates to a booster useful for enhancing the effects of ultrasound in the therapy of various diseases and a pharmaceutical liquid composition containing the booster and a medicament which shows enhanced diffusion and penetration of the medicament into the body by applying ultrasound. More particularly, it relates to a booster useful for therapy of various disease by applying ultrasound which comprises a plenty of microbubbles of a gas in a liquid, a pharmaceutical liquid composition comprising a plenty of microbubbles of a gas and a medicament in a liquid, and the use thereof in the therapy of various diseases while applying ultrasound.

Prior Art

It is known that various diseases are remedied by the aid of ultrasonic vibration. For example, it is described in Japanese Patent First Publication (Kokai) No. 115591/1977, etc. that percutaneous absorption of a medicament is enhanced by applying a ultrasonic vibration. Japanese Patent First Publication (Kokai) No. 180275/1990 discloses a drug-injecting device which is effective on the diffusion and penetration of the drug by applying a ultrasonic vibration in the step of injecting a drug into a human body via a catheter or a drug-injecting tube. U.S. Pat. Nos. 4,953,565 and 5,007,438 also disclose the technique of percutaneous absorption of medicaments by the aid of ultrasonic vibration. It is also reported that a tumor can be remedied by concentratedly applying ultrasound from outside the body.

In order to enhance the therapeutic effects with ultrasound, it is required to apply a higher energy of a ultrasonic vibration. However, too higher energy of a ultrasonic vibration causes disadvantageously burns or unnecessary heat at the portion other than the desired portion. On the other hand, when the energy of a ultrasonic vibration is lowered for eliminating such disadvantages, there is a problem of less effect of the ultrasound at the desired portion.

SUMMARY DESCRIPTION OF THE INVENTION

The present inventors have intensively studied on the enhancement of the effects of ultrasound with a lower energy of a ultrasonic vibration and have found that a booster comprising a plenty of microbubbles of a gas in a liquid is useful for the desired enhancement of the effects of ultrasound.

An object of the invention is to provide a booster useful for enhancing the effects of ultrasound which comprises a plenty of microbubbles of a gas in a liquid. Another object of the invention is to provide a pharmaceutical liquid composition containing the booster and a medicament which is useful for the therapy of various diseases together with the application of ultrasound. A further object of the invention is to provide a method for enhancing the effects by the application of ultrasound in the therapy of various diseases which comprises injecting the booster or the pharmaceutical liquid composition as set forth above into the portion to be remedied while applying ultrasound thereto. These and other objects and advantages of the invention will be apparent to those skilled in the art from the following description.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows a schematic view of one of the micro-bubbles contained in the booster of the invention.

FIG. 2 shows a schematic sectional view of one embodiment of a drug administration device used for injecting, pouring, applying or circulating the booster or the pharmaceutical liquid composition of the invention.

FIG. 3 shows a schematic sectional view of one embodiment of a drug administration device used for percutaneous injection of the booster or the pharmaceutical liquid composition of the invention.

FIG. 4 and FIG. 5 show graphs showing fibrinolysis by application of ultrasound with or without the booster of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The booster of the invention comprises a liquid containing a plenty of microbubbles of a gas having a diameter of 0.1 to 100 μm. The microbubbles are formed by entrapping microspheres of a gas into a liquid. The booster contains, for example, about 4107 of the microbubbles per one milliliter of a liquid. The microbubbles are made of various gases such as air, oxygen gas, carbon dioxide gas, inert gases (e.g. xenon, krypton, argon, neon, helium, etc.), preferably air and oxygen gas. The liquid includes any liquid which can form microbubbles, for example, human serum albumin (e.g. 3 to 5% human serum albumin), a physiological saline solution, a 5% aqueous glucose solution, an aqueous indocyanine green solution, autoblood, an aqueous solution of maglumine diatriazoate (=renografin), and any other X-ray contrast medium.

The booster can be prepared by a known method, for example, by agitating the liquid as mentioned above while blowing a gas as mentioned above into the liquid, or alternatively exposing the liquid to ultrasound with a sonicator under a gaseous atmosphere, whereby a vibration is given to the liquid to form microbubbles of the gas.

The pharmaceutical liquid composition of the invention comprises a plenty of microbubbles of a gas and a medicament in a liquid. The microbubbles of a gas and liquid are the same as mentioned above. The medicament includes any known medicaments effective for the desired therapy which can be absorbed percutaneously, for example, anti-thrombosis agents (e.g. urakinase, tissue plasminogen activator, etc.), hormones (e.g. insulin, etc.), theophylline, lidocaine, antibiotics, antineoplastic agents which are sensitive to ultrasound (e.g. doxorubicin (=adriamycin), cytarabine (=Ara-C), etc.), and the like. The medicament can be contained in a therapeutically effective amount as usually used. The pharmaceutical liquid composition can be prepared by mixing a medicament with a booster comprising a plenty of microbubbles of a gas in a liquid. The mixing ratio may vary depending on the desired amount and kind of the medicament and the kind of the liquid, but is usually in a range of 1:100 to 100:1 by weight (a medicament/a booster).

According to the invention, the therapeutic effects by ultrasound is boosted by the presence of a booster of the invention. Particularly, when a pharmaceutical liquid composition containing the booster and a medicament is poured or injected into a body in parenteral routes, such as intravenously, percutaneously or intramuscularly, while applying thereto a ultrasonic vibration, the therapeutic effects of the medicament is significantly enhanced. When a ultrasound from a ultrasonic element is applied to the liquid containing the booster and medicament, cavitation occurs in the liquid composition, and the medicament is diffused and penetrated into the desired portion of the biobody by the aid of vibration induced by the cavitation. The cavitation occurs when the level of vibration energy overs a certain threshold value. When the ultrasound is applied to the liquid composition of the invention, the threshold value of the vibration energy lowers due to the presence of a plenty of microbubbles of a gas. That is, the microbubbles of a gas act as nucleus of cavitation and thereby the cavitation occurs more easily. Accordingly, according to the invention, the desired ultrasonic energy necessary for the desired diffusion and penetration of a medicament is achieved even by less energy of ultrasonic vibration energy.

The desired ultrasound is applied by conventional ultrasonic devices which can supply a ultrasonic signal of 20 KHz to several MHz.

With reference to the accompanying drawing, the invention is illustrated in more detail.

FIG. 1 shows a schematic view of one of the plenty of microbubbles of a gas contained in the booster of the invention, wherein the microbubble of a gas has a diameter of 0.1 to 100 μm and is composed of a shell of human serum albumin (1) and gas (2) entrapped within the microbubble. The microbubbles are contained in a liquid (3) such as 5% human serum albumin solution in an amount of, for example, above 4107 cells/ml.

The booster is mixed with a medicament to give a pharmaceutical liquid composition. The pharmaceutical liquid composition is directly administered to the diseased part with an appropriate device, for example, with a drug administration device (4) as shown in FIG. 2. The drug administration device (4) comprises a base tube (5) to which the pharmaceutical liquid composition is supplied, and an end tube (6) which is to be inserted into the tissue of the biobody and through which the pharmaceutical liquid composition is poured or injected into the diseased part. The end tube (6) is provided with a ultrasonic element (7) (e.g. a cylindrical ceramic oscillator, etc.). The ultrasonic element (7) is supplied by a ultrasonic signal of 20 kHz to several MHz from a ultrasonic oscillation circuit (8) via a conductor (9a), connectors (10a) and (10b) provided on the side of the base tube (5), a part of the base tube (5) and a conductor (9b) provided within the end tube (6).

The application or injection of a medicament is carried out in the form of a pharmaceutical liquid composition which is prepared by previously mixing the medicament with the booster comprising a plenty of microbubbles of a gas in a liquid, wherein the medicament and the booster are mixed in a ratio of 1:100 to 100:1 by weight. The pharmaceutical liquid composition is poured into the base tube (5) from the supply opening (11) provided on the tip of the base tube (5), passes through a flow path (12) within the base tube (5) and a flow path (13) within the end tube (6) and then administered to the diseased part or the portion close thereto of the patient via a pouring opening (14) provided at the bottom of the end tube (6).

When the pharmaceutical liquid composition is administered into the diseased part or the portion close thereto through the pouring opening (14), a ultrasonic energy generated from a ultrasonic element (7) is given to the liquid composition, by which cavitation occurs owing to the ultrasonic energy. Microbubbles are formed at the occurrence of cavitation and when the microbubbles are decomposed, energy is generated, by which diffusion and penetration of the medicament is promoted. Since the pharmaceutical liquid composition contains a plenty of microbubbles of a gas, the microbubbles act as a nucleus for the cavitation, by which the cavitation occurs more easily, in other words, the threshold value of occurrence of cavitation lowers. Accordingly, it is possible to generate the cavitation with less energy than the case of using no booster.

When a ultrasonic vibration is applied to a liquid, if the liquid contains any material being able to become a nucleus, the cavitation occurs generally at a lower threshold value of energy, but it has been found that the cavitation occurs most easily where the liquid contains microbubbles of a gas having a diameter of 0.1 to 100 μm.

The drug administration device (4) as shown in FIG. 2 can be used, for example, for administering a pharmaceutical liquid composition into a blood vessel. For instance, in the treatment of coronary thrombosis, a pharmaceutical liquid composition comprising a booster of the invention and a urokinase is injected into the part of thrombosis or the close portion thereof with the drug administration device (4) where the tip of the end tube (6) is inserted into the portion close to the thrombosis with applying ultrasound, by which the thrombolytic effects of the medicament are significantly increased and further the blood flow is recovered within a shorter period of time in comparison with the administration of the medicament without the booster. The drug administation device (4) may also be used for the removing hematoma in bleeding of brain. For example, a pharmaceutical liquid composition comprising a booster of the invention and a thromolytic agent (e.g. urokinase) is administered to the portion of hematoma with the drug administration device (4) with applying ultrasound like the above, by which the hematoma is easily lysed.

In another embodiment of the invention, the pharmaceutical liquid composition can be administered percutaneously with a drug administration device (15) as shown in FIG. 3.

In the drug administration device (15) suitable for percutaneous administration of a medicament, a layer of a medicament (17) is provided below a ultrasonic element (16) (e.g. a disc shaped ceramic oscillator, etc.), under of which an adhesive layer (18) having a medicament permeability is laminated, whole of which is covered with a plastic cover (19). The ultrasonic element (16) is supplied by ultrasonic signal from a ultrasonic oscillation circuit provided outside via a connector (20) like in the drug administration device (4) as shown in FIG. 2.

In the device (15) of FIG. 3, a pharmaceutical liquid composition comprising a mixture of a booster and a medicament is contained in the layer of a medicament (17). When this device (15) is used, it is adhered onto the skin with facing the adhesive layer (18) to the skin, and then a ultrasonic signal is supplied to the ultrasonic element (16), by which a ultrasonic vibration from the ultrasonic element (16) is given to both of the medicament layer (17) and the skin and thereby the medicament contained in the medicament layer (17) is passed through the skin and is penetrated into the tissue to be treated. In this embodiment, since microbubbles of a gas are contained in the medicament layer (17), cavitation occurs easily within the medicament layer (17) by application of ultrasound, and hence even lower energy of the ultrasonic vibration is supplied from the ultrasonic element (16), the diffusion and penetration of the medicament can effectively be done to result in rapid absorption of the medicament.

The booster of the invention may also be used alone without mixing with a medicament in the therapy with ultrasound. For example, in the therapy of tumors by heating the diseased part of the tissue with ultrasound, that is, by concentratedly applying a ultrasonic vibration outside the biobody, a booster comprising a plenty of microbubbles of a gas in a liquid of the invention is previously injected into the blood vessel or to the portion close to the diseased part before application of ultrasound, by which the effect of heating with ultrasound is enhanced and thereby the therapeutic effects are significantly improved. In this embodiment, cavitation occurs also by the ultrasonic vibration more easily because of using a liquid containing microbubbles of a gas, and hence, even by less energy of the ultrasonic vibration suppled from the ultrasonic element, the ultrasonic energy sufficient to the therapy is obtained and thereby the undesirable burns and unnecessary heating at other portions can be avoided.

In the treatment of tumors, it is, of course, more effective to use it together with a chemotherapeutic agent suitable for the treatment of the tumors, by which the effects of the chemotherapeutic agent are more enhanced, where the diffusion and penetration of the medicament are improved owing to the booster.

The substance such as human serum albumin in the booster of the invention is easily metabolized within the biobody and excreted outside the biobody, and hence, it is not harmful to human body. Besides, the gas trapped within the microbubbles is extremely small and is easily dissolved in the blood fluid. Accordingly, the booster of the invention has no problem in the safety thereof.

The preparation of the booster and pharmaceutical liquid composition of the invention and effects thereof are illustrated by the following Examples and Experiment, but it should not be construed to be limited thereto.

EXAMPLE 1

Preparation of a Booster:

A 5% human serum albumin (8 ml) in a 10 ml-volume syringe is exposed to ultrasound with a sonicator (frequency, 20 KHz) by which vibration is given to the human serum albumin and a plenty of microbubbles of air are formed in the human serum albumin to give a booster comprising a human serum albumin containing a plenty of microbubbles of air.

EXAMPLE 2

Preparation of a Pharmaceutical Liquid Composition:

The 5% human serum albumin containing a plenty of microbubbles of air prepared in Example 1 is mixed with urokinase (concentration 1200 IU/ml) to give the desired pharmaceutical liquid composition.

Experiment 1. Forming Artificial Thrombosis

An artificial thrombosis was formed by Chandler's method. A blood (1 ml) collected from healthy human (two persons) was entered into a flexibale tube (inside diameter 3 mm, length 265 mm) and thereto was added calcium chloride, and then the tube was made a loop like shape, which was rotated at 12 r.p.m. for 20 minutes to give an artificial thrombosis model.

2. Ultrasonic Catheter

A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness 1 mm) was inserted into the tip of a cetheter (diameter 2 mm), and an oscillating element was connected to an oscillator provided outside with a fine connector passed through the catheter. A fine tube for pouring a test solution was provided at an opening opposite to the opening of the catheter end.

3. Test Method

The artificial thrombosis prepared above was added to a test tube together with a blood, and the ultrasonic catheter was inserted into the test tube so that the end of the catheter was set close to the portion of the artificial thrombosis (at a distance of about 5 mm), and to the test tube a mixture of urokinase and a booster prepared in Example 1 was added at a rate of 1 ml per minute, wherein urokinase (concentration 1200 IU/ml) and the booster were mixed immediately before pouring at a mixing ratio of 1:1 by weight. The mixture was refluxed while keeping the volume of the test solution at a constant level by removing excess volume of the solution by suction. The ultrasound (170 KHz) was exposed to the mixture by a pulse method (exposed for 2 seconds and stopped for 4 seconds) for 2 minutes (total exposing time 40 seconds). After the exposure, the ultrasonic catheter was removed from the test tube, and the mixture was incubated at 37 C. for 5 to 120 minutes, washed with a physiological saline solution several times and dried overnight. Thereafter, the dried mixture was weighed. As a control, the above was repeated by using only a physiological saline solution.

4. Test Results

The rate of fibrinolysis was calculated by the following equation: ##EQU1##

The results are shown in the accompanying FIGS. 4 and 5 wherein there are shown in average of twice tests.

FIG. 4 shows the results in the thrombosis prepared by using blood collected from one person, wherein the symbol -- is the data obtained in the addition of urokinase alone without exposure of ultrasound, - ♦- is the data obtained in the addition of urokinase alone with exposure of ultrasound, and -▪- is the data obtained in the addition of a mixture of urokinase and the booster with exposure of ultrasound.

As is shown in FIG. 4, the time for achieving 20% fibrinolysis was 45 minutes by urokinase alone without exposure of ultrasound, 30 minutes by a combination of urokinase and exposure of ultrasound, and only 10 minutes by a combination of a mixture of urokinase and a booster and exposure of ultrasound. The fibrinolytic effects of urokinase (both the rate of fibrinolysis and the fibrinlytic time) were signigicantly enhanced by using a booster with application of ultrasound.

FIG. 5 shows the results in the thrombosis prepared by using blood collected from another person and with reduced energy of ultrasound by 15%, wherein the symbols are the same as in FIG. 4. As is shown in FIG. 5, the fibrinolytic effects were significantly enhanced by using a mixture of urokinase and the booster. That is, in case of using urokinase alone with exposure of ultrasound, the 50% fibrinolysis was achieved by the treatment for 60 minutes, but in case of using a mixture of urokinase and the booster with exposure of ultrasound, it reduced to one fourth, i.e. it was achieved by the treatment only for 15 minutes.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2961382 *Jul 25, 1957Nov 22, 1960Ortho Pharma CorpUrokinase-a plasmiogen activator and methods of obtaining the same
US4466442 *Oct 13, 1982Aug 21, 1984Schering AktiengesellschaftCarrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4657756 *Sep 8, 1983Apr 14, 1987Schering AktiengesellschaftEnhancing ultrasonic images in blood stream; mono- and disaccharide suspensions
US4762915 *Jan 18, 1985Aug 9, 1988Liposome Technology, Inc.Protein-liposome conjugates
US4774958 *Oct 1, 1987Oct 4, 1988Feinstein Steven BHigh frequency sonication while heating of proteins, dispersion of microbubbles stabilized by protein
US4797285 *Dec 6, 1985Jan 10, 1989Yissum Research And Development Company Of The Hebrew University Of JerusalemLipsome/anthraquinone drug composition and method
US4844882 *Dec 29, 1987Jul 4, 1989Molecular Biosystems, Inc.Concentrated stabilized microbubble-type ultrasonic imaging agent
US4900540 *Jun 20, 1983Feb 13, 1990Trustees Of The University Of MassachusettsLipisomes containing gas for ultrasound detection
US4936281 *Apr 13, 1989Jun 26, 1990Everest Medical CorporationUltrasonically enhanced RF ablation catheter
US5040537 *Nov 21, 1988Aug 20, 1991Hitachi, Ltd.Method and apparatus for the measurement and medical treatment using an ultrasonic wave
US5069664 *Jan 25, 1990Dec 3, 1991Inter Therapy, Inc.Intravascular ultrasonic angioplasty probe
US5088499 *Aug 20, 1990Feb 18, 1992Unger Evan CLiposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5209720 *Jun 18, 1991May 11, 1993Unger Evan CMethods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5215680 *Jul 10, 1990Jun 1, 1993Cavitation-Control Technology, Inc.Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5216130 *May 17, 1990Jun 1, 1993Albany Medical CollegeCoupling polysaccharide spacer arm to central albumin core of complex; radioactive labels
AU634470A * Title not available
EP0224934A2 *Dec 5, 1986Jun 10, 1987Steven B. FeinsteinContrast agent, process for its preparation and its use for ultrasonic imaging
EP0278074A2 *Nov 23, 1987Aug 17, 1988Shunro TachibanaApparatus for the endermic application of medicines
EP0327490A1 *Feb 1, 1989Aug 9, 1989Schering AktiengesellschaftUltrasonic imaging agents, process for their preparation and their diagnostic and therapeutical use
GB1577551A * Title not available
JPH02180275A * Title not available
JPS52115591A * Title not available
WO1980002365A1 *May 2, 1980Nov 13, 1980Rasor Ass IncUltrasonic image enhancement
WO1989005159A1 *Dec 2, 1988Jun 15, 1989Schering AgUltrasonic or shock wave operating process and agent for implementing said process
WO1989005160A1 *Dec 2, 1988Jun 15, 1989Schering AgUse of media containing bubbles in shock wave and ultrasonic therapy
WO1990001971A1 *Aug 18, 1989Mar 8, 1990Massachusetts Inst TechnologyUltrasound enhancement of transbuccal drug delivery
Non-Patent Citations
Reference
1 *B.D. Butler, J. clin. Ultrasound 14(5): 408 12 (Jun. 1986).
2B.D. Butler, J. clin. Ultrasound 14(5): 408-12 (Jun. 1986).
3 *Bleeker et al., J. Ultrasound, Med. 9(8): 461 71 (Aug. 1990).
4Bleeker et al., J. Ultrasound, Med. 9(8): 461-71 (Aug. 1990).
5 *Douglas L. Miller et al; Sonoporation of Cultured Cells in the Rotation Tube Exposure System, vol. 25, No. 1, 1999.
6 *Evan C. Unger et al. Acoustically Active Liposheres Containing Paclitaxel, vol. 11, No. 12, 1992.
7 *Evan C. Unger et al.; Ultrasound Enhances Gene Expression of Liposomal Transfection. Vol. 32, No. 12, Dec. 1997.
8 *F. Prat et al.; In Vivo Effects of Cavitation Alone or in Combination Wity Chemotherapy in a Peritoneal Carcinomatosis in the Rat. vol. 68, pp. 13 17.
9F. Prat et al.; In Vivo Effects of Cavitation Alone or in Combination Wity Chemotherapy in a Peritoneal Carcinomatosis in the Rat. vol. 68, pp. 13-17.
10 *Feinstein et al., J. Am. Coll. Cardiol. 3(1): 14 20 (Jan. 1984).
11Feinstein et al., J. Am. Coll. Cardiol. 3(1): 14-20 (Jan. 1984).
12 *Holland et al., J. Acoust. Soc. Am. 88(5): 2059 2069 (Nov. 1990).
13Holland et al., J. Acoust. Soc. Am. 88(5): 2059-2069 (Nov. 1990).
14 *Keller er al., J. Ultrasound Med. 5(9): 493 8 (Sept. 1986).
15Keller er al., J. Ultrasound Med. 5(9): 493-8 (Sept. 1986).
16 *Lang et al., Circulation 75(1): 229 234 (Jan. 1987).
17Lang et al., Circulation 75(1): 229-234 (Jan. 1987).
18 *Leong et al., Biomaterials, vol. 7: 364 371 (Sep. 1986).
19Leong et al., Biomaterials, vol. 7: 364-371 (Sep. 1986).
20 *Meltzer et al., J. Clin. Ultrasound 8(2): 121 7 (Apr. 1980).
21Meltzer et al., J. Clin. Ultrasound 8(2): 121-7 (Apr. 1980).
22 *R.J. Jeffers et al.; Evaluation of the Effect of Cavitation Activity on Drug Ultrasound Synergisms, 1993.
23R.J. Jeffers et al.; Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms, 1993.
24 *Richard Price et al.; Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created By Targeted Microbubble Destruction With Ultrasound, Sep. 29, 1998.
25 *Russell Jeffers et al.; Bimethylformamide as an Enhancer of Cavitation Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
26Russell Jeffers et al.; Bimethylformamide as an Enhancer of Cavitation-Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
27 *Shiping Bao et al.; Transfection of a Reporter plasmid into Cultured Cells By Sonoporation In Vitro. vol. 23, Nov. 6, 1997.
28 *T.T. Kirn, Medical news & Perspectives, JAMA 261(11): 1542 (Mar. 17, 1989).
29 *Tachibana K.; Tachibana S.; Albumin Microbubble Echo Contrast Materials as an Enhancer For Ultrasound Accelerated Thrombolysis, Sep. 1, 1995.
30Tachibana K.; Tachibana S.; Albumin Microbubble Echo-Contrast Materials as an Enhancer For Ultrasound Accelerated Thrombolysis, Sep. 1, 1995.
31 *Thomas R. Porter et al.; Thrombolytic Enhancement With Perfluorocarbon Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.
32Thomas R. Porter et al.; Thrombolytic Enhancement With Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.
33 *Vanderberg et al., Am. Heart J., 11574, 733 9 (Apr. 1988).
34Vanderberg et al., Am. Heart J., 11574, 733-9 (Apr. 1988).
35 *Wheatley et al., Biomaterials 11(19): 713 7 (Nov. 1990).
36Wheatley et al., Biomaterials 11(19): 713-7 (Nov. 1990).
37 *William J. Greenleaf et al.; Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. vol. 24, No. 4 pp. 587 595, 1998.
38William J. Greenleaf et al.; Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. vol. 24, No. 4 pp. 587-595, 1998.
39 *Yunqiu Wu et al.; Binding as Lysing of Blood Clots Using MRX 408, May 1998.
40Yunqiu Wu et al.; Binding as Lysing of Blood Clots Using MRX-408, May 1998.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6478754 *Apr 23, 2001Nov 12, 2002Advanced Medical Applications, Inc.Ultrasonic method and device for wound treatment
US6514221 *Jul 26, 2001Feb 4, 2003Brigham And Women's Hospital, Inc.Blood-brain barrier opening
US6569099Jan 12, 2001May 27, 2003Eilaz BabaevUltrasonic method and device for wound treatment
US7141044Dec 11, 2002Nov 28, 2006Ekos CorporationAlternate site gene therapy
US7211248Jul 10, 2002May 1, 2007Sonogene, L.L.C.Controlling lipid metabolism; injecting a solution of Dna, Rna gene using gas microbubbles using ultrasonic frequency; gene expression
US7267778May 3, 2004Sep 11, 2007Ashland Licensing And Intellectual Property LlcHas ultrasound emitter located relative to compartment of container holding liquid medium and microbubble emitter relative to compartment; produces water supersaturated with salts to induce biotoxic effects on microorganisms
US7404906Mar 9, 2006Jul 29, 2008Ashland Licensing & Intellectual Property LlcDevice and process for treating cutting fluids using ultrasound
US7448859May 10, 2007Nov 11, 2008Ashland Licensing And Intellectual Property LlcDevices and method for treating cooling fluids utilized in tire manufacturing
US7514009Jan 6, 2006Apr 7, 2009Ashland Licensing And Intellectual Property LlcDevices and processes for use in ultrasound treatment
US7588547Jan 17, 2006Sep 15, 2009Cabochon Aesthetics, Inc.Methods and system for treating subcutaneous tissues
US7601128Jan 17, 2006Oct 13, 2009Cabochon Aesthetics, Inc.Apparatus for treating subcutaneous tissues
US7632413Nov 4, 2003Dec 15, 2009Ashland Licensing And Intellectual Property LlcTreat blood with ultrasound, ultraviolet radiation, infrared, microwaves; without cavitation, heating, ozone; luekemia, viral blood infections, cancers
US7717853Aug 15, 2005May 18, 2010Henry NitaMethods and apparatus for intracranial ultrasound delivery
US7718073Aug 3, 2007May 18, 2010Ashland Licensing And Intellectual Property LlcTreat blood with ultrasound, ultraviolet radiation, infrared, microwaves; without cavitation, heating, ozone; luekemia, viral blood infections, cancers
US7803168Dec 9, 2005Sep 28, 2010The Foundry, LlcAortic valve repair
US7878991Aug 31, 2007Feb 1, 2011Bacoustics, LlcPortable ultrasound device for the treatment of wounds
US7967763Dec 2, 2005Jun 28, 2011Cabochon Aesthetics, Inc.Method for treating subcutaneous tissues
US8097170May 12, 2010Jan 17, 2012Ashland Licensing And Intellectual Property LlcProcess for treating a liquid medium
US8366620Apr 30, 2010Feb 5, 2013Henry NitaMethods and apparatus for intracranial ultrasound delivery
US8366643Sep 14, 2009Feb 5, 2013Cabochon Aesthetics, Inc.System and method for treating subcutaneous tissues
US8740835Feb 17, 2011Jun 3, 2014Ekos CorporationTreatment of vascular occlusions using ultrasonic energy and microbubbles
EP2727544A1Nov 5, 2013May 7, 2014Ekos CorporationCatheter systems and methods
WO2002066060A2 *Feb 18, 2002Aug 29, 2002Berlien Hans-PeterMethod and device for ultrasound-assisted transmembrane medicament application in vitro
WO2003051208A1Dec 16, 2002Jun 26, 2003Ekos CorpBlood flow reestablishment determination
Classifications
U.S. Classification604/22, 601/2, 424/94.63, 424/94.6
International ClassificationA61K49/22, A61K9/00, A61K41/00, A61K9/50
Cooperative ClassificationA61K49/223, A61K9/0009, A61K41/0028, A61K41/0004, A61K9/5052, A61K41/0047
European ClassificationA61K9/00L8, A61K49/22P4, A61K41/00T, A61K41/00D, A61K41/00M, A61K9/50H6H
Legal Events
DateCodeEventDescription
Jul 6, 2004CCCertificate of correction
Jan 20, 2004ASAssignment
Owner name: EKOS L.L.C., WASHINGTON
Free format text: LICENSE AGREEMENT;ASSIGNORS:TACHIBANA, SHUNRO;TACHIBANA, KATSURO;REEL/FRAME:014892/0626
Effective date: 19960122
Owner name: EKOS L.L.C. 22030 - 20TH AVENUE SE., SUITE 101BOTH
Free format text: LICENSE AGREEMENT;ASSIGNORS:TACHIBANA, SHUNRO /AR;REEL/FRAME:014892/0626
Jan 28, 2002ASAssignment
Owner name: EKOS CORPORATION, WASHINGTON
Free format text: MERGER;ASSIGNOR:EKOS CORPORATION;REEL/FRAME:012495/0109
Effective date: 20011119
Owner name: EKOS CORPORATION 22030 20TH AVENUE SE, #101 BOTHEL
Owner name: EKOS CORPORATION 22030 20TH AVENUE SE, #101BOTHELL
Free format text: MERGER;ASSIGNOR:EKOS CORPORATION /AR;REEL/FRAME:012495/0109